Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 19/20 | 1.00 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7961042 | 0.91 | CMA1 (0.83) | CMA1CTSGPOLB | |
| SCHEMBL1851876 | 0.91 | CMA1 (0.83) | CMA1CTSG | |
| SCHEMBL3418056 | 0.89 | CMA1 (1.00) | CMA1POLB | |
| SCHEMBL18900823 | 0.88 | CMA1 (0.79) | CMA1CTSGPOLB | |
| SCHEMBL7951279 | 0.87 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL7960258 | 0.83 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL18900837 | 0.82 | CMA1 (0.77) | CMA1CTSGPOLB | |
| SCHEMBL6115259 | 0.82 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL7960485 | 0.82 | CMA1 (0.84) | CMA1CTSG | |
| SCHEMBL18900824 | 0.81 | CMA1 (0.67) | CMA1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323991-B1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| EP-2323991-B1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-05-31 | — | — | EP | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-8969348-B2 | Chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-03-03 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20120129863-A1 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-24 | — | — | US | disclosed |
| WO-2010019417-A2 | CHYMASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129863-A1 | CHYMASE INHIBITORS | CMA1, CPA3, SERPINB1 | CMA1 1/4885CTSG 14/4885POLB 2228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.